PURE BiosciencePURE -4.67% EBITDA Margin % is -102.37% as of Apr. 2026. The stock has 5 warning signs investors should review. Among 1,953 Consumer Packaged Goods companies, PURE Bioscience ranks worse than 96.62% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PURE Bioscience's EBITDA for the
three
months ended in Apr. 2026 was $-0.52 Mil. PURE Bioscience's Revenue for the
three
months ended in Apr. 2026 was $0.51 Mil. Therefore, PURE Bioscience's EBITDA margin for the quarter that ended in Apr. 2026 was -102.37%.
PURE Bioscience (OTCPK:PURE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PURE Bioscience EBITDA Margin % Related Terms
PURE Bioscience EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PURE Bioscience's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PURE vs RAY, DSY, TANH: EBITDA Margin % Comparison
For the Household & Personal Products subindustry, PURE Bioscience's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PURE Bioscience EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PURE Bioscience's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PURE Bioscience (PURE) has a EBITDA Margin % of -102.37% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PURE Bioscience and its competitors. According to the industry distribution chart, PURE Bioscience ranks #1887 out of 1953 companies in the Consumer Packaged Goods industry, placing it in the top 96.6%.
Is PURE Bioscience's EBITDA Margin % too high?
PURE Bioscience's current EBITDA Margin % is -102.37%. Based on the distribution chart, PURE Bioscience ranks #1887 out of 1953 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers.
How does PURE Bioscience's EBITDA Margin % compare to RAY and DSY?
According to the Consumer Packaged Goods industry distribution chart, PURE Bioscience ranks #1887 out of 1953 companies for EBITDA Margin %. This places PURE Bioscience in the lower half of its industry. The industry median EBITDA Margin % is 9.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 9.00, based on 1,953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PURE Bioscience and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 9.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PURE Bioscience's current EBITDA Margin % is -102.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PURE Bioscience stock overvalued right now?
Based on GuruFocus' analysis, PURE Bioscience (PURE) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.07 — trading 33.3% below its estimated fair value. The current EBITDA Margin % is -102.37%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PURE Bioscience (PURE), the current EBITDA Margin % is -102.37% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, and products preserved with SDC and SDC as a raw material ingredient for manufacturing use. The company generates revenue from the sale of its antimicrobial products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PURE has been successfully added to your 